Dr. Meyers on Low-Dose Tamoxifen vs Placebo After Surgery for DCIS Breast Cancer
Cancer Network spoke with Marleen Meyers, MD, about evidence on  low-dose tamoxifen vs placebo in women who had surgery for their ductal carcinoma in situ. (Source: CancerNetwork)
Source: CancerNetwork - June 17, 2019 Category: Cancer & Oncology Authors: Marleen Meyers, MD Source Type: news

The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: A large study from a single institution
(Cancer Research UK) Upcoming publication from the British Journal of Cancer, investigating HER2 expression as a predictor of recurrence and development in patients with DCIS. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 7, 2019 Category: Cancer & Oncology Source Type: news

ASBrS: Less-invasive mastectomy safe for more women
A type of mastectomy that leaves the surface of the breast intact is a safe...Read more on AuntMinnie.comRelated Reading: Contrast mammo equals MRI for measuring tumor size Racial factors affect time to breast cancer treatment Breast MRI helps guide DCIS treatment Women still need breast imaging after mastectomy Breast cancer follow-up imaging varies widely (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 3, 2019 Category: Radiology Source Type: news

Six Prognostic Factors ID ’ d for Invasive Disease After DCIS
Six significant factors include African - American race, premenopausal status, detection by palpation (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 25, 2019 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pathology, Journal, Source Type: news

Six Factors Tied to DCIS Returning as Breast Cancer Six Factors Tied to DCIS Returning as Breast Cancer
A group of six factors are associated with ductal carcinoma in situ returning as invasive breast cancer after treatment.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 25, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Six Prognostic Factors ID'd for Invasive Disease After DCIS
THURSDAY, April 25, 2019 -- In a review published online April 25 in Cancer Epidemiology, Biomarkers& Prevention, six prognostic factors are identified that may predict invasive disease after a diagnosis of ductal carcinoma in situ... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 25, 2019 Category: Pharmaceuticals Source Type: news

Six factors may predict invasive breast cancer recurrence after DCIS diagnosis
(American Association for Cancer Research) Six factors were associated with invasive recurrence of breast cancer after a diagnosis of ductal carcinoma in situ (DCIS), according to data from a meta-analysis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 25, 2019 Category: Cancer & Oncology Source Type: news

Smart Biopsy Device Could Diagnose Breast Cancer Using Miniature Radiofrequency Sensors
Normally, when a physician notices a suspicious mass or lesion on a mammogram, he or she will request an ultrasound to explore it further. Based on those results, a biopsy may be performed to determine whether the mass is cancerous. “Unfortunately, right now, in some cases, physicians either overdiagnose or underdiagnose based on that biopsy, because with ultrasound they can only see so much,” said Lori Chmura, CEO of Dune Medical Devices. “The doctor is essentially going in blindly, trying to see what looks like the most suspicious area, and they’re t...
Source: MDDI - March 12, 2019 Category: Medical Devices Authors: Susan Shepard Tags: Business Source Type: news

Stereotactic radiation extends long-term survival
for some patients with stage...Read more on AuntMinnie.comRelated Reading: ASTRO: SABR is effective for oligometastatic cancers ASTRO: Weekly breast radiation therapy is safe ASTRO: AI's rad therapy future is in predicting outcomes Is radiation therapy warranted for DCIS postlumpectomy? ASTRO: Short radiation course safe for breast cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 31, 2019 Category: Radiology Source Type: news

Breast MRI effective as adjunct to DBT in high-risk women
Breast MRI is an effective adjunct screening technology for women at high risk...Read more on AuntMinnie.comRelated Reading: Breast MRI helps guide DCIS treatment Tissue enhancement on breast MRI informs cancer risk Breast MRI works for evaluating equivocal DBT findings High-risk women benefit from twice-yearly breast MRI Can Tetris inspire AI for MRI breast cancer detection? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 25, 2019 Category: Radiology Source Type: news

Breast MRI helps guide DCIS treatment
Breast MRI -- along with tests that characterize breast cancer genes -- can...Read more on AuntMinnie.comRelated Reading: Breast MRI works for evaluating equivocal DBT findings High-risk women benefit from twice-yearly breast MRI Breast MRI underutilized in high-risk women Breast MRI improves PPV for BI-RADS category 4B lesions Multiparametric MRI shines for suspected breast cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 21, 2019 Category: Radiology Source Type: news

Using Radiation Therapy to Reduce Recurrence in DCIS
Cancer Network spoke with Dr. Carmen Bergom about advancements in the treatment of DCIS and the importance of using local recurrence patterns to help guide future research. (Source: CancerNetwork)
Source: CancerNetwork - January 17, 2019 Category: Cancer & Oncology Authors: Carmen Bergom, MD, PhD Source Type: news

Tissue enhancement on breast MRI informs cancer risk
Elevated levels of background parenchymal enhancement on breast MRI increase...Read more on AuntMinnie.comRelated Reading: Breast MRI effective for postpartum breast cancer The 'ins and outs' of imaging dense breasts Normal tissue enhancement on breast MR predicts cancer risk Breast MRI CAD doesn't improve accuracy due to poor DCIS detection (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 14, 2019 Category: Radiology Source Type: news

Go Low With Tamoxifen for DCIS Go Low With Tamoxifen for DCIS
In a potentially practice-changing result, use of a 5-mg daily dose of tamoxifen for patients with ductal carcinoma in situ (DCIS) prevented new and recurrent breast cancer events in comparison with placebo.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 7, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Low-dose tamoxifen reduced recurrence and new disease for patients with DCIS, LCIS, and ADH
(American Association for Cancer Research) Treatment with a low dose of tamoxifen (5 mg per day) halved the risk of disease recurrence and new disease for women who had been treated with surgery following a diagnosis of breast intraepithelial neoplasia compared with placebo, and it did not cause more serious adverse events, according to data from the randomized, phase III TAM-01 clinical trial presented at the 2018 San Antonio Breast Cancer Symposium. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 6, 2018 Category: Cancer & Oncology Source Type: news